[CAS NO. 618913-30-7] AZD5904
PRODUCTS SPECIFICATIONS [618913-30-7]
DESCRIPTION [618913-30-7]
Overview
| MDL | MFCD31619279 |
|---|---|
| Molecular Weight | 252.29 |
| Molecular Formula | C10H12N4O2S |
| SMILES | O=C1NC(N(C[C@@H]2OCCC2)C3=C1N=CN3)=S |
7 Publications Citing Use of MCE
Summary
AZD5904 is a selective and irreversible inhibitor of human Myeloperoxidase ( MPO ) with an IC 50 of 140 nM and has similar potency in mouse and rat.
IC50 & Target
IC50: 140 nM (human MPO) [1]
In Vitro
AZD5904 is a pselective and irreversible inhibitor of human Myeloperoxidase (MPO) with an IC 50 of 140 nM and has similar potency in mouse and rat. It is 10 to 19-fold selective compare to the closely related lactoperoxidase and thyroid peroxidase; >70-fold to a broad panel of other enzymes, ion channels, and receptors. In isolated human neutrophils, 1 µM AZD5904 inhibits PMA stimulated HOCl by >90% [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 396.37 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.9637 mL | 19.8185 mL | 39.6369 mL |
| 5 mM | 0.7927 mL | 3.9637 mL | 7.9274 mL |
| 10 mM | 0.3964 mL | 1.9818 mL | 3.9637 mL |
-
1.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (8.24 mM); Clear solution
References
- [1] Myeloperoxidase (MPO) inhibitor.
- [2] Tidén AK, Sjögren T, Svensson M, et al. 2-thioxanthines are mechanism-based inactivators of myeloperoxidase that block oxidative stress during inflammation. J Biol Chem. 2011;286(43):37578-37589.
- [3] Chai W, Aylor K, Liu Z, Gan LM, Michaëlsson E, Barrett E. Inhibiting myeloperoxidase prevents onset and reverses established high-fat diet-induced microvascular insulin resistance. Am J Physiol Endocrinol Metab. 2019;317(6):E1063-E1069.
- [4] Ramachandra CJA, Kp MMJ, Chua J, et al. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes. Cardiovasc Res. 2022;118(2):517-530.